

notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Board of Scientific Advisors.

Date: June 22, 2000.

Time: 8:30 AM to 6:00 PM.

Agenda: Report of the Director, NCI; Ongoing and New Business, Special Initiative Updates, Budget Presentation, and RFA Concept Reviews.

Place: 900 Rockville, Pike, Building 31, Conference Room 10, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, PhD, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Rm. 8141, Bethesda, MD 20892.

This notice is being published less than 15 days prior to the meeting due to scheduling changes.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-14747 Filed 6-9-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given to the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, National Cooperative Drug Discovery Group.

Date: June 7-9, 2000.

Time: 7:00 PM to 5:00 PM

Agenda: To review and evaluate grant applications.

Place: Gaithersburg Hilton, 620 Perry Park, Gaithersburg, MD 20877.

Contact Person: C.M. Kerwin, PhD, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8086, Rockville, MD 20892-7405, 301/496-7421.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-14748 Filed 6-9-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel.

Date: June 19, 2000.

Time: 1 pm to 4 pm.

Agenda: To review and evaluate contract proposals.

Place: 6700B Rockledge Drive, Room 2148, Bethesda, MD 20817. (Telephone Conference Call)

Contract Person: Hagit S. David, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural

Activities, NIAID, NIH, Room 2217, 6700-B Rockledge Drive, MSC, 7610, Bethesda, MD 20892-7610, 301-496-2550.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: June 2, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00-14746 Filed 6-9-00; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Antagonists of the $\alpha\text{E}\beta_7$ Integrin as Therapeutic Agents for Inflammatory Diseases

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. § 209 (c) (1) and 37 CFR § 404.7 (a) (1) (i), that the National Institutes of Health, Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in PCT Patent Application S/ N PCT/US99/27817 (filed November 23, 1999) based on U.S. Patent Application 60/109,957 (filed November 25, 1998), entitled "Antagonists of the $\alpha\text{E}\beta_7$ Integrin as Therapeutic Agents for Inflammatory Diseases", to BioSeek, Inc., having a place of business in San Francisco, CA. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to $\alpha\text{E}\beta_7$ -related human therapeutics for the treatment of inflammatory diseases.

DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before August 11, 2000 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Vasant Gandhi, J.D., Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7056, X224;
Facsimile (301) 402-0220; E-mail
vg48q@nih.gov.

SUPPLEMENTARY INFORMATION: The pathogenesis of inflammatory reactions may depend upon the traffic of inflammatory mediating cells from sites of induction to sites of inflammation. This trafficking is known to be mediated, in part, by the interaction of the integrin, $\alpha^4\beta_7$, and the addressin, mucosa addressin cell adhesion molecule-1. This homing, which governs the entry of cells into tissues, is accompanied by additional adhesion molecule-ligand interactions that ensure the retention of cells in the target tissue.

The inventors believe the integrin, $\alpha^E\beta_7$, may play a role in retaining intraepithelial lymphocytes in the intraepithelial site via its interaction with E-cadherin. Experiments have shown in IL-2^{-/-} mice, that administration of anti- $\alpha^E\beta_7$ can prevent colonic inflammation and reverse pre-existing inflammation. This data is important because it strongly suggests that both entry and retention of cells are necessary for the induction and maintenance of colitis in these IL-2^{-/-} mice. The present technology relates to methods for treating inflammatory reactions for but not necessarily limited to: autoimmune diseases, graft-versus-host disease and transplantation rejections.

The prospective exclusive license: will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. § 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. § 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. § 552.

Dated: June 1, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 00-14749 Filed 6-9-00; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4560-C-08]

FY 2000 Super Notice of Funding Availability (SuperNOFA) for HUD's Housing, Community Development and Empowerment Programs and Section 8 Housing Voucher Assistance; Amendment to Funding Availability Announcement for Economic Development Initiative (EDI); Extension of Application Due Date for Regional Economic Development Projects

AGENCY: Office of the Secretary, HUD.

ACTION: Super Notice of Funding Availability (SuperNOFA) for HUD Grant Programs; Amendment to EDI Announcement—Extension of EDI Regional Application Due Date.

SUMMARY: On February 24, 2000, HUD published its Fiscal Year (FY) 2000 Super Notice of Funding Availability (SuperNOFA) for HUD's Housing, Community Development, and Empowerment Programs and Section 8 Housing Voucher Assistance. This document extends the application due date to apply for funding for regional economic development projects under the Economic Development Initiative (EDI). This application due date extension is only for the regional economic development project applications.

DATES: The application due date for EDI regional economic development projects applications is extended by this notice to July 14, 2000.

FOR FURTHER INFORMATION CONTACT: You may contact either Tony Johnston or Paul Webster of the Office of Economic Development Department of Housing and Urban Development, 451 Seventh Street, SW, Room 7136, Washington, DC 20410; telephone (202) 708-1871 (this is not a toll-free number). Persons with speech or hearing impairments may access this number via TTY by calling the toll-free Federal Information Relay Service at 1-800-877-8339. You may also call the SuperNOFA Information Center, which you may reach by calling 1-800-HUD-8929 or the Center's TTY number at 1-800-HUD-2209. Other than the "800" number, these numbers are not toll-free.

SUPPLEMENTARY INFORMATION: On February 24, 2000 (65 FR 9322), HUD published its Fiscal Year (FY) 2000 Super Notice of Funding Availability (SuperNOFA) for HUD's Housing, Community Development, and Empowerment Programs and Section 8 Housing Voucher Assistance. The FY 2000 SuperNOFA announced the

availability of approximately \$2.424 billion in HUD program funds covering 39 grant categories within programs operated and administered by HUD offices and Section 8 housing voucher assistance. The FY 2000 SuperNOFA included HUD's funding availability announcement for the Economic Development Initiative (EDI). The EDI section of the SuperNOFA announced the availability of approximately \$24.1 million in EDI funds to stimulate economic development by local governments and private sector parties.

This document extends the application due date to apply for funding for regional economic development projects under the Economic Development Initiative (EDI) to July 14, 2000. This application due date extension is only for regional economic development project applications. It has been brought to HUD's attention that the amount of time necessary to collect and compile the information necessary for a regional economic development project application is more time consuming than that required for general economic development project applications. Accordingly, HUD is providing additional time to prepare and submit regional economic development project applications. (Please note that the EDI application due was extended previously to June 13, 2000, for all applications by notice published in the **Federal Register** on May 9, 2000 (65 FR 26844).)

Please note that applicants that already submitted applications for regional economic development projects by the June 13, 2000, application due date, need not resubmit a new application and need not amend their applications. Applicants that already submitted applications for regional economic development projects, however, may submit new or amended applications if they choose to do so. Applicants that already submitted applications and plan to submit new or amended applications should clearly identify whether the information submitted is new and replaces a previously submitted application in its entirety or is an addendum or amendment to the previously submitted application.

The funding availability announcement for EDI is found at page 9787 of the February 24, 2000 SuperNOFA. The original announcement contains all the information with respect to EDI application contents and where to submit EDI applications. This notice only provides the extended due date for